Drug Discovery Today: Technologies最新文献_第9页

A critical evaluation of the approaches to targeted protein degradation for drug discovery 药物发现靶向蛋白质降解方法的关键评估。

Drug Discovery Today: Technologies Pub Date : 2019-04-01 DOI: 10.1016/j.ddtec.2019.02.002

Rajesh Chopra, Amine Sadok, Ian Collins

{"title":"A critical evaluation of the approaches to targeted protein degradation for drug discovery","authors":"Rajesh Chopra, Amine Sadok, Ian Collins","doi":"10.1016/j.ddtec.2019.02.002","DOIUrl":"10.1016/j.ddtec.2019.02.002","url":null,"abstract":"<div><p>There is a great deal of excitement around the concept of targeting proteins for degradation as an alternative to conventional inhibitory small molecules and antibodies. Protein degradation can be undertaken by bifunctional molecules that bind the target for ubiquitin mediated degradation by complexing them with Cereblon (CRBN), von Hippel-Lindau or other E-3 ligases. Alternatively, E-3 ligase receptors such as CRBN or DCAF15 can also be used as a ‘template’ to bind IMiD or sulphonamide like compounds to degrade multiple context specific proteins by the selected E-3 ligases. The ‘template approach’ results in the degradation of neo-substrates, some of which would be difficult to drug using conventional approaches. The chemical properties necessary for drug discovery, the rules by which neo-substrates are selected by E-3 ligase receptors and defining the optimal components of the ubiquitin proteasome for protein degradation are still to be fully elucidate. Theis review will aim to critically evaluate the different approaches and principles emerging for targted protein degradation.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":"31 ","pages":"Pages 5-13"},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2019.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37332833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30

Miniaturised ‘antibody’-drug conjugates for solid tumours? 用于实体瘤的小型化“抗体”-药物结合物?

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.09.006

Mahendra P. Deonarain

引用次数: 15

Bispecifics and antibody–drug conjugates: A positive synergy 双特异性和抗体-药物缀合物:积极的协同作用

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.09.003

Antoine Maruani

引用次数: 28

Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy 抗体偶联纳米颗粒作为抗体药物偶联化疗的一种新形式

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.10.003

Michael C. Johnston, Christopher J. Scott

引用次数: 57

Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity? 使用吡咯苯二氮卓类药物和相关的共价结合dna相互作用分子作为ADC有效载荷:机制是否与全身毒性有关?

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.10.004

Paul J.M. Jackson , Syafiq Kay , Ilona Pysz , David E. Thurston

引用次数: 16

Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals 位点特异性螯合剂-抗体偶联PET和SPECT成像与放射性金属

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.10.002

Mauricio Morais, Michelle T. Ma

{"title":"Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals","authors":"Mauricio Morais, Michelle T. Ma","doi":"10.1016/j.ddtec.2018.10.002","DOIUrl":"10.1016/j.ddtec.2018.10.002","url":null,"abstract":"<div><p>Antibodies and their derivatives radiolabelled with positron- and gamma-emitting radiometals enable sensitive and quantitative molecular Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) imaging of antibody distribution in vivo. Chelators that are covalently attached to antibodies allow radiolabelling with metallic PET and SPECT radioisotopes. Conventional strategies for chelator-protein conjugation generate heterogeneous mixtures of bioconjugates that can exhibit reduced affinity for their receptor targets, and undesirable biodistribution and pharmacokinetics. Recent advances in bioconjugation technology enable site-specific modification to generate well-defined constructs with superior properties. Herein we survey existing site-specific chelator-protein conjugation methods. These include chelator attachment to cysteines/disulfide bonds or the glycan region of the antibody, enzyme-mediated chelator conjugation, and incorporation of sequences of amino acids that chelate the radiometal. Such technology will allow better use of PET and SPECT imaging in the development of antibody-based therapies.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":"30 ","pages":"Pages 91-104"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2018.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36774362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 45

Antibody – Drug conjugates (ADC) – Drug discovery today: Technologies 抗体-药物偶联物(ADC) -今天的药物发现:技术

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.11.003

Vijay Chudasama

引用次数: 6

Drawing lessons from the clinical development of antibody-drug conjugates 从抗体-药物偶联物的临床发展中吸取教训

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.10.001

Robert Lyon

引用次数: 40

Minireview: Addressing the retro-Michael instability of maleimide bioconjugates 综述:探讨马来酰亚胺生物偶联物的反迈克尔不稳定性

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.07.002

Peter A. Szijj, Calise Bahou, Vijay Chudasama

引用次数: 61

Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery 探索替代抗体支架:靶向药物递送的抗体片段和抗体模拟物

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI: 10.1016/j.ddtec.2018.10.005

Daniel A. Richards

{"title":"Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery","authors":"Daniel A. Richards","doi":"10.1016/j.ddtec.2018.10.005","DOIUrl":"10.1016/j.ddtec.2018.10.005","url":null,"abstract":"<div><p>The field of targeted therapeutics has benefitted immeasurably from the development of high-affinity antibodies. These important ligands have facilitated the development of effective therapies, particularly when conjugated to potent cytotoxic payloads i.e. in antibody–drug conjugates (ADCs). The success of ADCs is evidenced by rapid adoption within the pharmaceuticals community; many major companies have dedicated ADC research programmes. However, despite the advantages, the field of ADCs has failed to live up to its full potential. Studies have emerged suggesting that traditional IgG scaffolds may not be the optimal format for targeted payload delivery. In response, the protein engineering community has begun to explore alternative high-binding protein scaffolds as antibody mimics. In this short review I will summarise the generation, modification, and application of emerging antibody fragments and synthetic antibody mimics, with a focus on their use as drug carriers. The review aims to highlight the advantages of antibody mimics, and how they could be employed to overcome the issues and limitations of traditional ADCs.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":"30 ","pages":"Pages 35-46"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2018.10.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36774443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50